OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
optinose.com
1020 Stony Hill Road, Yardley, 19067, US
Details
Year founded
2010
Revenue
75M-200M
Employees
51-200
Number of locations
3
NAICS
325413
SIC
2834
Products & Services
Outlines the company's specialized services and operational strengths.
- Antitrust
- Certification
- Code of Conduct
- Contact us in order to access
Equipment
Provides a detailed list of machinery and tools utilized on the company's premises.
- Bi-Directional™ Exhalation Delivery Systems (EDS)
- Liquid Delivery Device
- Powder Delivery Device
- Contact us in order to access
Ramping up production
Indicates the company's current production trend and growth trajectory.
TRUE
Our production algorithm is showing that optinose is ramping up production.
Target industries
Employees working in OptiNose, Inc.
News
OptiNose, Inc. (NASDAQ:OPTN) Short Interest Down 19.4% in June
OptiNose, Inc. (NASDAQ:OPTN) Short Interest Down 19.4% in June
OptiNose, Inc. (NASDAQ:OPTN - Get Free Report) was the target of a significant decrease in short interest during the month of June. As of June 15th,...
Locations (3)
OptiNose, Inc.
1020 Stony Hill Road, Yardley, 19067, US
OptiNose, Inc.
Oslo Innovation Center Oslo, . Gaustedelleen 0349, NO
OptiNose, Inc.
Berkeley House Hunts Rise South Marston, Wiltshire SN3 4TG, GB
People Also Searched For
Frequently Asked Questions
What services & capabilities does OptiNose, Inc. offer?
OptiNose, Inc. offers a range of services and capabilities, including Antitrust.
What kind of equipment does OptiNose, Inc. use?
OptiNose, Inc. uses a variety of equipment, including Bi-Directional™ Exhalation Delivery Systems (EDS).
What are the target industries of OptiNose, Inc.?
OptiNose, Inc. serves several industries, including the medical industry.
How many locations does OptiNose, Inc. operate?
OptiNose, Inc. operates from 3 locations.
What is the annual revenue of OptiNose, Inc.?
OptiNose, Inc.'s revenue is $76.28M.
Where are the headquarters of OptiNose, Inc.?
The headquarters of OptiNose, Inc. are located in 1020 stony hill road, yardley, pennsylvania 19067, united states.
What is the NAICS code for OptiNose, Inc.?
The NAICS code for OptiNose, Inc. is 325413.
How many employees does OptiNose, Inc. have?
OptiNose, Inc. has 141 employees.
What is the official website of OptiNose, Inc.?
The official website of OptiNose, Inc. is https://www.optinose.com.
When was OptiNose, Inc. founded?
OptiNose, Inc. was founded in 2010.